Latest Conference Articles

Cortes Discusses Changing Landscape of Hematology and Challenges to the Cancer Center of Today
Research Shows Promise for Directing Later Lines of Therapy for Hodgkin Lymphoma

Research Shows Promise for Directing Later Lines of Therapy for Hodgkin Lymphoma

October 2nd 2022, 2:29pm

SOHO Annual Meeting

Research now is addressing how subsequent therapies can meet needs of patients with Hodgkin lymphoma who progress after early lines of treatment.

Relapse Less Likely With Orca-T vs Standard Transplant in Hematologic Malignancies

Relapse Less Likely With Orca-T vs Standard Transplant in Hematologic Malignancies

October 1st 2022, 4:06pm

SOHO Annual Meeting

In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.

Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?

Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?

October 1st 2022, 2:22pm

SOHO Annual Meeting

Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.

Precise Selection of Treatment for Follicular Lymphoma

Precise Selection of Treatment for Follicular Lymphoma

September 30th 2022, 7:43pm

SOHO Annual Meeting

When choosing a treatment regimen for follicular lymphoma, an individualized approach is necessary, according to Loretta J. Nastoupil, MD.

Future Directions for MPN Research

Future Directions for MPN Research

September 30th 2022, 7:42pm

SOHO Annual Meeting

Srdan Verstovsek, MD, PhD, highlights what future research in myeloproliferative neoplasms looks to examine.

Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma

Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma

September 30th 2022, 7:00pm

SOHO Annual Meeting

As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.

Emerging EZH 1/2 Inhibitors Demonstrate Single-Agent Efficacy in R/R PTCL

Emerging EZH 1/2 Inhibitors Demonstrate Single-Agent Efficacy in R/R PTCL

September 30th 2022, 5:30pm

SOHO Annual Meeting

Novel targets continue to emerge through clinical trials in peripheral T0cell lymphoma, in particular EZH 1 and EZH 2 inhibitors, which have strong single-agent efficacy.

Potential of Menin Inhibitors Is Focus of AML Session

Potential of Menin Inhibitors Is Focus of AML Session

September 30th 2022, 5:00pm

SOHO Annual Meeting

AUGMENT-101 demonstrates the potential of menin inhibitors for the treatment of patients with acute myeloid leukemia.

Second-Line BCL Treatment Landscape Shifts From ASCT to CAR T-Cell Therapy

Second-Line BCL Treatment Landscape Shifts From ASCT to CAR T-Cell Therapy

September 30th 2022, 4:00pm

SOHO Annual Meeting

Chimeric antigen receptor T-cell therapy provides a new option for patients with relapsed/refractory B-cell lymphoma.